Page 238 - Haematologica Vol. 110 - January 2025
P. 238
LETTER TO THE EDITOR A
B
Figure 1. Meta-analysis of the progression-free survival and overall survival in the real-world and randomized clinical trial co- horts. (A) summarizes the progression-free survival (PFS) and (B) overall survival (OS) in real-world (RW) versus randomized clin- ical (RCT) patient cohorts with multiple myeloma (MM), stratified by regimens used in the newly diagnosed MM (NDMM) versus relapsed refractory MM (RRMM) treatment setting. Rd: lenalidomide and dexamethasone; VRd: bortezomib, lenalidomide and dexamethasone; Kd: carfilzomib and dexamethasone; KRd: carfilzomib and Rd; DVd: daratumumab, bortezomib and dexameth- asone; DRd: daratumumab and Rd; Pd: pomalidomide and dexamethasone; CI: confidence interval.
Haematologica | 110 January 2025
230
